Lupus & antiphospholipid syndrome
New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review
Authors' conclusion
The pipeline of investigational drugs in SLE is highly diversified and will hopefully enable more optimal Treat-To-Target with the goal of disease modification.
Study context
- Population
- Targeted therapies in clinical development in Systemic Lupus Erythematosus (SLE) registered in clinicaltrials.gov
- Participants
- 92 participants203 clinical trials
- Comparison
- bDMARDs vs targeted synthetic [ts]DMARDs
- bDMARDsn = 58
- Targeted synthetic [ts]DMARDsn = 34
- Outcome
- Targeted therapies in clinical development in SLE
Methodological detailsclinicaltrials.gov search (28th of August 2022), most advanced stage of clinical development per drug
- clinicaltrials.gov search (28th of August 2022)
- Most advanced stage of clinical development per drug
Pooled result
As reported in the abstract
- Phase I
- 20
- Phase Ia/IIb
- 6
- Phase II
- 51
- Phase II/III
- 1
- Phase III
- 13
- Phase IV
- 1
- Target: inflammatory cytokines, chemokines or their receptors
- 19
- Target: intracellular signaling pathways
- 18
- Target: B cells
- 14
- Target: plasma cells
- 7
- Target: T/B cell co-stimulation molecules
- 10
- Target: complement molecules
- 5
- Target: T lymphocytes
- 2
- Target: plasmacytoid dendritic cells
- 2
- Target: various other immune targets
- 15
Further pooled results
Trial status
- Recruiting
- 31
- Active but not recruiting
- 8
- Not yet recruiting
- 4
- Enrolling by invitation
- 2
- Completed
- 31
- Prematurely terminated
- 12
- Withdrawn
- 1
- Status unknown
- 3
Original publication
New biologics and targeted therapies in systemic lupus: From new molecular targets to new indications. A systematic review. Joint Bone Spine. Published 7 January 2023. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →